Cargando…
The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome
The sulfonylurea drug gliquidone is FDA approved for the treatment of type 2 diabetes. Binding of gliquidone to ATP-sensitive potassium channels (SUR1, Kir6 subunit) in pancreatic β-cells increases insulin release to regulate blood glucose levels. Diabetes has been associated with increased levels o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587901/ https://www.ncbi.nlm.nih.gov/pubmed/34776934 http://dx.doi.org/10.3389/fnagi.2021.754123 |
_version_ | 1784598290420989952 |
---|---|
author | Kim, Jieun Park, Jin-Hee Shah, Keshvi Mitchell, Scott John Cho, Kwangwook Hoe, Hyang-Sook |
author_facet | Kim, Jieun Park, Jin-Hee Shah, Keshvi Mitchell, Scott John Cho, Kwangwook Hoe, Hyang-Sook |
author_sort | Kim, Jieun |
collection | PubMed |
description | The sulfonylurea drug gliquidone is FDA approved for the treatment of type 2 diabetes. Binding of gliquidone to ATP-sensitive potassium channels (SUR1, Kir6 subunit) in pancreatic β-cells increases insulin release to regulate blood glucose levels. Diabetes has been associated with increased levels of neuroinflammation, and therefore the potential effects of gliquidone on micro- and astroglial neuroinflammatory responses in the brain are of interest. Here, we found that gliquidone suppressed LPS-mediated microgliosis, microglial hypertrophy, and proinflammatory cytokine COX-2 and IL-6 levels in wild-type mice, with smaller effects on astrogliosis. Importantly, gliquidone downregulated the LPS-induced microglial NLRP3 inflammasome and peripheral inflammation in wild-type mice. An investigation of the molecular mechanism of the effects of gliquidone on LPS-stimulated proinflammatory responses showed that in BV2 microglial cells, gliquidone significantly decreased LPS-induced proinflammatory cytokine levels and inhibited ERK/STAT3/NF-κB phosphorylation by altering NLRP3 inflammasome activation. In primary astrocytes, gliquidone selectively affected LPS-mediated proinflammatory cytokine expression and decreased STAT3/NF-κB signaling in an NLRP3-independent manner. These results indicate that gliquidone differentially modulates LPS-induced microglial and astroglial neuroinflammation in BV2 microglial cells, primary astrocytes, and a model of neuroinflammatory disease. |
format | Online Article Text |
id | pubmed-8587901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85879012021-11-13 The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome Kim, Jieun Park, Jin-Hee Shah, Keshvi Mitchell, Scott John Cho, Kwangwook Hoe, Hyang-Sook Front Aging Neurosci Aging Neuroscience The sulfonylurea drug gliquidone is FDA approved for the treatment of type 2 diabetes. Binding of gliquidone to ATP-sensitive potassium channels (SUR1, Kir6 subunit) in pancreatic β-cells increases insulin release to regulate blood glucose levels. Diabetes has been associated with increased levels of neuroinflammation, and therefore the potential effects of gliquidone on micro- and astroglial neuroinflammatory responses in the brain are of interest. Here, we found that gliquidone suppressed LPS-mediated microgliosis, microglial hypertrophy, and proinflammatory cytokine COX-2 and IL-6 levels in wild-type mice, with smaller effects on astrogliosis. Importantly, gliquidone downregulated the LPS-induced microglial NLRP3 inflammasome and peripheral inflammation in wild-type mice. An investigation of the molecular mechanism of the effects of gliquidone on LPS-stimulated proinflammatory responses showed that in BV2 microglial cells, gliquidone significantly decreased LPS-induced proinflammatory cytokine levels and inhibited ERK/STAT3/NF-κB phosphorylation by altering NLRP3 inflammasome activation. In primary astrocytes, gliquidone selectively affected LPS-mediated proinflammatory cytokine expression and decreased STAT3/NF-κB signaling in an NLRP3-independent manner. These results indicate that gliquidone differentially modulates LPS-induced microglial and astroglial neuroinflammation in BV2 microglial cells, primary astrocytes, and a model of neuroinflammatory disease. Frontiers Media S.A. 2021-10-29 /pmc/articles/PMC8587901/ /pubmed/34776934 http://dx.doi.org/10.3389/fnagi.2021.754123 Text en Copyright © 2021 Kim, Park, Shah, Mitchell, Cho and Hoe. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Aging Neuroscience Kim, Jieun Park, Jin-Hee Shah, Keshvi Mitchell, Scott John Cho, Kwangwook Hoe, Hyang-Sook The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome |
title | The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome |
title_full | The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome |
title_fullStr | The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome |
title_full_unstemmed | The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome |
title_short | The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome |
title_sort | anti-diabetic drug gliquidone modulates lipopolysaccharide-mediated microglial neuroinflammatory responses by inhibiting the nlrp3 inflammasome |
topic | Aging Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587901/ https://www.ncbi.nlm.nih.gov/pubmed/34776934 http://dx.doi.org/10.3389/fnagi.2021.754123 |
work_keys_str_mv | AT kimjieun theantidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT parkjinhee theantidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT shahkeshvi theantidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT mitchellscottjohn theantidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT chokwangwook theantidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT hoehyangsook theantidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT kimjieun antidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT parkjinhee antidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT shahkeshvi antidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT mitchellscottjohn antidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT chokwangwook antidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome AT hoehyangsook antidiabeticdruggliquidonemodulateslipopolysaccharidemediatedmicroglialneuroinflammatoryresponsesbyinhibitingthenlrp3inflammasome |